NorthCoast Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

NorthCoast Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.42M	Buy	+7,500	New	+$1.41M	0.05%	216

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NorthCoast Asset Management's ALNY Position: Q3 2021 in Review

NorthCoast Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2021: 7,500 shares worth $1.42M. The stake represents 0.05% of the portfolio and ranks #216 among its holdings.

404 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

NorthCoast Asset Management held 7,500 shares of Alnylam Pharmaceuticals worth $1.42M as of Q3 2021.
Alnylam Pharmaceuticals was a new NorthCoast Asset Management position in Q3 2021.
Alnylam Pharmaceuticals made up 0.05% of NorthCoast Asset Management's portfolio in Q3 2021, its #216 holding.
404 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on NorthCoast Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.